- Home
- SLG vs IRON Comparison
SLG vs IRON Comparison
Compare SLG & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | IRON |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLG | IRON |
|---|---|---|
| Price | $40.88 | $61.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 12 |
| Target Price | $53.84 | ★ $101.67 |
| AVG Volume (30 Days) | ★ 1.4M | 923.6K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $101.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.03 | $30.82 |
| 52 Week High | $66.91 | $99.50 |
Technical Indicators
Market Signals| Indicator | SLG | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 37.06 |
| Support Level | $40.26 | $57.45 |
| Resistance Level | $47.34 | $65.34 |
| Average True Range (ATR) | 2.25 | 5.98 |
| MACD | 0.31 | 0.02 |
| Stochastic Oscillator | 90.00 | 62.47 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.